SUPHA PHARMACHEM LIMITED

Trades and distributes pharmaceutical chemicals, with operations routed through a Singapore subsidiary that drives nearly all of its consolidated revenue. On a consolidated basis, Q2 FY26 revenue from operations was Rs. 11,105.82 lakh and consolidated profit after tax was Rs. 862.34 lakh in the same quarter, while the standalone Indian entity reported only Rs. 857.79 lakh in revenue and a profit after tax of Rs. 20.12 lakh for H1 FY26, showing that the standalone Indian trading book has shrunk sharply. The company describes itself as expanding contract development and manufacturing (CDMO) capabilities through its overseas arm, Remlife Global PTE, which is the main contributor to consolidated revenue and profit. The Singapore subsidiary's delayed financial reporting has repeatedly held up the parent's consolidated results. On the cost side, FY25 employee cost was Rs. 0.76 crore (0.2% of revenue) and other operating expenses were Rs. 7.45 crore (1.8% of revenue), with a thin EBITDA margin of 2.4%. The company is currently under the Corporate Insolvency Resolution Process (CIRP) admitted by NCLT Mumbai on 17 March 2026 on a Section 9 petition by operational creditor Boston Ivy Healthcare Solutions over unpaid chemical supply invoices of Rs. 7.47 crore, with the Resolution Professional in charge and the prior board's powers suspended.